Table 3.

Multivariate Analysis by Cox’s Proportional Hazards Model on Intermediate- and High-Grade Non-Hodgkin’s Lymphoma

Category Estimate Value ± SE P ValueHazards Ratio
Overall survival  
nm23-H1(<80/≥80 ng/mL)  1.96 ± 0.39  .0001  7.087  
 Age (<60/≥60 yr)  1.35 ± 0.49  .0053  3.877 
 Performance status (0, 1/2 ∼ 4)  1.05 ± 0.54  .0511 2.847  
 Immunophenotype (T/B)  0.42 ± 0.43  .3293 1.519  
 Soluble CD44 (<1,000/≥1,000 ng/mL) 0.39 ± 0.49  .4278  1.473  
 IPI (L, L-I/H-I, H) 0.18 ± 0.53  .7394  1.192  
 Soluble IL-2 receptor (<1,000/≥1,000 U/mL)  0.18 ± 0.53  .7394  1.192 
 LDH (normal/>normal)  0.12 ± 0.62  .8428  1.132 
  
PFS  
nm23-H1 (<80/≥80 ng/mL) 1.48 ± 0.33  .0001  4.400  
 Age (<60/≥60 yr) 0.67 ± 0.38  .0753  1.955  
 Performance status (0, 1/2 ∼ 4)  1.52 ± 0.43  .0004  4.573 
 Immunophenotype (T/B)  0.37 ± 0.33  .2710  0.693 
 IPI (L, L-I/H-I, H)  0.35 ± 0.45  .4432  0.707 
 Soluble IL-2 receptor (<1,000/≥1,000 U/mL)  0.17 ± 0.36 .6408  1.185  
 LDH (normal/>normal)  0.58 ± 0.48 .2244  1.793 
Category Estimate Value ± SE P ValueHazards Ratio
Overall survival  
nm23-H1(<80/≥80 ng/mL)  1.96 ± 0.39  .0001  7.087  
 Age (<60/≥60 yr)  1.35 ± 0.49  .0053  3.877 
 Performance status (0, 1/2 ∼ 4)  1.05 ± 0.54  .0511 2.847  
 Immunophenotype (T/B)  0.42 ± 0.43  .3293 1.519  
 Soluble CD44 (<1,000/≥1,000 ng/mL) 0.39 ± 0.49  .4278  1.473  
 IPI (L, L-I/H-I, H) 0.18 ± 0.53  .7394  1.192  
 Soluble IL-2 receptor (<1,000/≥1,000 U/mL)  0.18 ± 0.53  .7394  1.192 
 LDH (normal/>normal)  0.12 ± 0.62  .8428  1.132 
  
PFS  
nm23-H1 (<80/≥80 ng/mL) 1.48 ± 0.33  .0001  4.400  
 Age (<60/≥60 yr) 0.67 ± 0.38  .0753  1.955  
 Performance status (0, 1/2 ∼ 4)  1.52 ± 0.43  .0004  4.573 
 Immunophenotype (T/B)  0.37 ± 0.33  .2710  0.693 
 IPI (L, L-I/H-I, H)  0.35 ± 0.45  .4432  0.707 
 Soluble IL-2 receptor (<1,000/≥1,000 U/mL)  0.17 ± 0.36 .6408  1.185  
 LDH (normal/>normal)  0.58 ± 0.48 .2244  1.793 
Close Modal

or Create an Account

Close Modal
Close Modal